phrykt

Hims & Hers Health, Inc. (HIMS): who owns it and who trades it

As of Nov 16, 2026, HIMS insiders reported 45 open-market sales worth $19.3M and 1 purchase worth $1.2M in the last 12 months, with 99% of the sale value made under pre-set 10b5-1 plans. The largest seller was Oluyemi Okupe (CFO), with $9.7M. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Hims & Hers Health

From the latest filings

Overall: more buying than selling. Funds and famous investors mostly bought. Insiders was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns HIMS

507 funds and institutions reported HIMS shares worth $5.7B at the end of Q2 2026. The largest holder is BlackRock, Inc. with $995M.

10 largest owners, by value

BlackRock, Inc.$995M
Vanguard Portfolio Management LLC$366M
Vanguard Capital Management LLC$331M
State Street Corp$282M
California State Teachers Retirement System$231M
Morgan Stanley$248M
Divisadero Street Capital Management, LP$208M
Geode Capital Management, LLC$197M
Goldman Sachs Group Inc$179M
JPMorgan Chase & Co$159M

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.28.70M–$995M+9%
Vanguard Portfolio Management LLC10.56M–$366M+4%
Vanguard Capital Management LLC9.54M–$331M+2%
State Street Corp8.15M–$282M+9%
California State Teachers Retirement System8.00M–$231M+3405%
Morgan Stanley7.15M–$248M-20%
Divisadero Street Capital Management, LP6.01M–$208M+1179%
Geode Capital Management, LLC5.68M–$197M+9%
Goldman Sachs Group Inc5.17M–$179M+111%
JPMorgan Chase & Co4.77M–$159M–
FMR LLC (Fidelity)4.32M–$150M–
Marshall Wace, LLP4.22M–$146M+482%
UBS Group AG2.66M–$92.3M-36%
Northern Trust Corp2.59M–$89.9M+6%
Charles Schwab Investment Management Inc2.45M–$85.1M+4%
Sixth Street Partners Management Company, L.P.2.45M–$85.1M–
State of Michigan Retirement System2.35M–$81.3M+0%
Bank of America Corp2.31M–$80.2M-47%
Principal Financial Group Inc1.67M–$57.8M+30%
Vanguard Fiduciary Trust Co1.52M–$52.8M+5%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, HIMS insiders reported $1.2M of open-market purchases and $19.3M of sales. 99% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$1.2M
1 trades, 1 people
Sales, 12 months
$19.3M
45 trades, 8 people
Sales under a 10b5-1 plan
99%
Share of sale value
Latest trade
Oct 28, 2026
Filed Oct 29, 2026

Purchases and sales by month

$5.2M$5.2MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 28, 2026Soleil BoughtonChief Legal OfficerSale plan3,462$27.60$95.6KForm 4
Oct 14, 2026Soleil BoughtonChief Legal OfficerSale plan3,461$29.06$101KForm 4
Oct 1, 2026Oluyemi OkupeCFOSale plan2,000$29.70$59.4KForm 4
Sep 30, 2026Soleil BoughtonChief Legal OfficerSale plan3,461$29.17$101KForm 4
Sep 22, 2026Oluyemi OkupeCFOSale plan29,277$29.95$877KForm 4
Sep 17, 2026Oluyemi OkupeCFOSale plan12,313$28.82$355KForm 4
Sep 16, 2026Soleil BoughtonChief Legal OfficerSale plan6,236$27.86$174KForm 4
Sep 15, 2026Michael ChiChief Operating OfficerSale plan14,027$28.39$398KForm 4
Sep 15, 2026Mohamed ElshenawyCTOSale plan7,954$28.39$226KForm 4
Sep 2, 2026Soleil BoughtonChief Legal OfficerSale plan3,458$28.33$98KForm 4
Aug 19, 2026Oluyemi OkupeCFOSale plan4,938$29.99$148KForm 4
Aug 19, 2026Soleil BoughtonChief Legal OfficerSale plan25,111$27.55$692KForm 4
Aug 18, 2026Deborah M. AutorDirectorSale plan16,773$27.85$467KForm 4
Aug 17, 2026Oluyemi OkupeCFOSale plan9,388$27.89$262KForm 4
Jul 17, 2026Oluyemi OkupeCFOSale plan7,163$31.99$229KForm 4
Jul 6, 2026Oluyemi OkupeCFOSale plan7,163$36.49$261KForm 4
Jun 22, 2026Oluyemi OkupeCFOSale plan18,197$34.03$619KForm 4
Jun 18, 2026Oluyemi OkupeCFOSale plan55,383$35.09$1.9MForm 4
Jun 18, 2026Patrick Harrison CarrollChief Medical OfficerSale plan23,726$35.00$830KForm 4
Jun 17, 2026Michael ChiChief Operating OfficerSale plan14,027$31.50$442KForm 4
Jun 17, 2026Irene BecklundPAOSale plan4,490$31.50$141KForm 4
Jun 17, 2026Mohamed ElshenawyCTOSale plan30,040$31.50$946KForm 4
Jun 16, 2026Irene BecklundPAOSale plan7,573$30.25$229KForm 4
May 26, 2026David B WellsDirectorPurchase48,400$24.24$1.2MForm 4
May 18, 2026Oluyemi OkupeCFOSale plan7,950$23.64$188KForm 4
Apr 20, 2026Soleil BoughtonChief Legal OfficerSale plan9,463$30.00$284KForm 4
Apr 20, 2026Oluyemi OkupeCFOSale plan19,645$29.96$589KForm 4
Apr 17, 2026Oluyemi OkupeCFOSale plan18,005$27.83$501KForm 4
Apr 16, 2026Oluyemi OkupeCFOSale plan36,922$25.90$956KForm 4
Apr 6, 2026Oluyemi OkupeCFOSale plan3,975$19.98$79.4KForm 4
Mar 20, 2026Oluyemi OkupeCFOSale plan9,217$23.77$219KForm 4
Mar 17, 2026Irene BecklundPAOSale plan5,529$24.69$137KForm 4
Mar 17, 2026Soleil BoughtonChief Legal OfficerSale plan4,812$24.69$119KForm 4
Mar 17, 2026Michael ChiChief Operating OfficerSale plan97,289$24.69$2.4MForm 4
Feb 27, 2026Soleil BoughtonChief Legal OfficerSale plan4,651$15.21$70.7KForm 4
Feb 3, 2026Oluyemi OkupeCFOSale plan5,262$26.44$139KForm 4
Jan 20, 2026Oluyemi OkupeCFOSale plan9,067$30.34$275KForm 4
Jan 5, 2026Oluyemi OkupeCFOSale plan9,070$33.79$306KForm 4
Dec 22, 2025Oluyemi OkupeCFOSale plan23,090$35.72$825KForm 4
Dec 17, 2025Michael ChiChief Operating OfficerSale plan13,750$36.71$505KForm 4
Dec 17, 2025Deborah M. AutorDirectorSale plan7,054$36.71$259KForm 4
Dec 17, 2025Patrick Harrison CarrollDirectorSale plan10,021$36.71$368KForm 4
Dec 17, 2025Irene BecklundPAOSale plan8,411$36.71$309KForm 4
Dec 9, 2025Garcia Andrea G PerezDirectorSale2,500$39.17$97.9KForm 4
Nov 24, 2025Soleil BoughtonChief Legal OfficerSale plan2,631$35.22$92.7KForm 4
Nov 17, 2025Oluyemi OkupeCFOSale plan23,187$36.81$854KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Oluyemi OkupeChief Financial Officer–$9.7MOct 1, 2026
Michael ChiChief Operating Officer–$3.7MSep 15, 2026
Soleil BoughtonChief Legal Officer–$1.8MOct 28, 2026
Patrick Harrison CarrollChief Medical Officer, Director–$1.2MJun 18, 2026
David B WellsDirector$1.2M–May 26, 2026
Mohamed ElshenawyCTO–$1.2MSep 15, 2026
Irene BecklundPAO–$816KJun 17, 2026
Deborah M. AutorChief Policy Officer, Director–$726KAug 18, 2026
Garcia Andrea G PerezDirector–$97.9KDec 9, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

HIMS short interest

51.66M HIMS shares are sold short. Over the last 12 reports the number of shares short went down 18%.

As of Oct 30, 2026, 51.66M HIMS shares were sold short, down 3.4% from the report before. At the average daily volume of 8.84M shares, buying them all back would take about 5.8 trading days (days to cover).

Shares short

51.66MMay 15Oct 3067.55M

Days to cover

5.8May 15Oct 306.7

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202651.66M–-3%8.84M5.8
Oct 15, 202653.47M–-2%10.68M5.0
Sep 30, 202654.77M–+3%10.41M5.3
Sep 15, 202652.92M–-4%8.64M6.1
Aug 31, 202654.95M–-6%12.70M4.3
Aug 14, 202658.67M–-6%13.08M4.5
Jul 31, 202662.22M–+1%16.75M3.7
Jul 15, 202661.41M–+0%13.58M4.5
Jun 30, 202661.17M–-7%18.92M3.2
Jun 15, 202665.47M–+5%18.56M3.5
May 29, 202662.61M–-1%19.91M3.1
May 15, 202663.37M–+0%25.86M2.5

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Members of Congress who traded HIMS

Since Nov 17, 2024, 1 member of Congress reported 1 purchase and 0 sales of HIMS. The latest was a purchase by Lisa C. McClain on Aug 4, 2025, reported Sep 12, 2025.

Purchases 1Sales 0

Reported trades

Trade dateMemberTypeAmountOwnerReportedSource
Aug 4, 2025Lisa C. McClain (R-MI)Purchase$1K–$15KSpouseSep 12, 2025Report

Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work

Hims & Hers Health company events

Hims & Hers Health filed 15 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 9, 2026.

  1. Nov 9, 2026LeadershipThe board of directors of Hims & Hers Health, Inc. increased the size of the Board from nine to ten directors and appointed Dr. Andrew Huberman, 51, to fill the newly created directorship, effective immediately. Filing
  2. Nov 9, 2026AnnouncementHims & Hers Health’s Disclosure Channels To Disseminate Information Investors of the Company and others should note that we announce information to the public about the Company, the products and services available on the Company’s platform, and other updates regarding the Company through a variety… Filing
  3. Oct 7, 2026LeadershipJonathan M. Franklin commenced employment with Hims & Hers Health, Inc. as chief accounting officer. Filing
  4. Aug 10, 2026ResultsReleased financial results. Filing
  5. Jul 17, 2026LeadershipIrene Becklund informed Hims & Hers Health, Inc. of her intention to resign as Chief Accounting Officer and Principal Accounting Officer, effective as of October 9, 2026. Filing
  6. Jul 1, 2026AgreementXeCare LLC and Apostrophe Pharmacy LLC, subsidiaries of Hims & Hers Health, Inc., entered into a Master Receivables Purchase Agreement with JPMorgan Chase Bank, N.A., as purchaser (in such capacity, the “ Purchaser ”). Filing
  7. Jun 15, 2026VoteReported shareholder vote results. Filing
  8. Jun 2, 2026AgreementHims & Hers Health, Inc., as borrower, entered into Amendment No. 3 to the Revolving Credit and Guaranty Agreement, dated as of February 18, 2025 (as amended by that certain Amendment No. 1 to the Revolving Credit and Guaranty Agreement, dated as of June 25, 2025, that certain Amendment No. 2 to… Filing
  9. May 21, 2026AgreementThe Company issued $402.5 million of Notes. Filing
  10. May 19, 2026AnnouncementHims & Hers Health, Inc. issued a press release relating to its proposed private offering of Convertible Senior Notes due 2032 to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Filing
  11. May 11, 2026ResultsReleased financial results. Filing
  12. Mar 11, 2026AnnouncementShared information with investors. Filing
  13. Feb 23, 2026ResultsReleased financial results. Filing
  14. Feb 19, 2026AgreementHims & Hers Health, Inc., Hims, Inc., and Horizon BidCo Pty Ltd ACN 694 778 375, an Australian proprietary company and wholly-owned subsidiary of the Company, entered into a Securities Sale Deed with the sellers party thereto, pursuant to which, among other things, the Sellers agreed to sell and… Filing
  15. Nov 17, 2025AnnouncementThe Board of Directors of Hims & Hers Health, Inc. authorized and approved a new share repurchase program pursuant to which the Company may repurchase up to $250.0 million of its Class A common stock. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Hims & Hers Health financials

Famous investors that hold HIMS

5 of the 50 well-known investors we track reported holding HIMS in their latest 13F filing. The largest position is Ken Griffin's, worth $14.3M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026479,984$14.3M0.0%-43%
Paul Tudor Jones · Tudor Investment CorpQ3 2026396,003$11.8M0.1%+207%
Israel Englander · Millennium ManagementQ3 2026132,943$4M0.0%New
Ray Dalio · Bridgewater AssociatesQ3 202682,335$2.5M0.0%+1070%
Larry Robbins · Glenview Capital ManagementQ3 202619,800$590K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named HIMS in the last 120 days.

FiledHolderFormStake
Nov 16, 2026G1 Execution Services, LLC13G/A4.8%
Nov 16, 2026G1 Execution Services, LLC13G/A4.8%
Oct 30, 2026Vanguard Capital Management13G/A5.0%
Oct 30, 2026Vanguard Capital Management13G/A5.0%

Questions about Hims & Hers Health, Inc. (HIMS) stock

Hims & Hers Health runs an online health platform. Customers see licensed providers through the app and get prescriptions and products for hair loss, sexual health, skin care and weight loss. Andrew Dudum co-founded the company and is its chief executive.

Does Andrew Dudum control Hims & Hers?

He holds most of the votes. Hims & Hers has two classes of stock. Class A shares, which trade on the market, carry one vote each. Class V shares carry 175 votes each and are held by trusts linked to Dudum. At the June 2026 annual meeting there were about 222.5 million Class A shares and 8.4 million Class V shares. By that count, the Class V shares alone carried about 87% of the votes.

The two classes vote together. Dudum's say comes mainly from the Class V shares, not from the size of his economic stake.

Have Hims & Hers insiders sold stock?

In the 12 months to November 9, 2026, insiders reported 45 open-market sales worth about $19.3 million. About 99% of the sale value was under pre-set Rule 10b5-1 plans. Chief financial officer Oluyemi Okupe sold about $9.7 million and chief operating officer Michael Chi about $3.7 million.

There was one open-market purchase. Director David Wells bought 48,400 shares, about $1.2 million, on May 26, 2026. See insider buying vs insider selling.

How many Hims & Hers shares are sold short?

As of October 15, 2026, 53.5 million shares were sold short, down 2.4% from the report before. At the average daily volume of 10.7 million shares, it would take about 5 trading days to buy them all back. The number of shares short fell 16% over the last 11 reports. See what short interest is and days to cover.

What board and leadership changes did Hims & Hers report in 2026?

A Form 8-K filed November 9, 2026 says the board grew from nine to ten directors and appointed Dr. Andrew Huberman to the new seat, effective immediately. In October 2026 Jonathan Franklin started as chief accounting officer.

At the end of Q2 2026, 507 funds and institutions reported Hims & Hers shares. BlackRock's holding was the largest, worth about $995 million. In October 2026 Vanguard Capital Management filed an amended Schedule 13G reporting a 5.0% stake. See Schedule 13D vs 13G.

Who owns the most HIMS stock?

The largest reported owner of Hims & Hers Health, Inc. (HIMS) is BlackRock, Inc.. In total, 507 funds and institutions reported holding HIMS at the end of Q2 2026. See the largest owners.

Are HIMS insiders buying or selling?

In the last 12 months, HIMS insiders reported 1 open-market purchase worth $1.2M and 45 sales worth $19.3M. The latest trade was on Oct 28, 2026. See every trade.

What is the short interest in HIMS?

As of Oct 30, 2026, 51.66M HIMS shares were sold short, down 3.4% from the report before. At the average daily volume of 8.84M shares, buying them all back would take about 5.8 trading days (days to cover). See the history.

Have members of Congress traded HIMS?

Yes. 1 member of Congress reported 1 purchase and 0 sales of HIMS since Nov 17, 2024. The latest was reported on Sep 12, 2025. See the trades.

Which famous investors hold HIMS?

5 of the 50 well-known investors we track reported HIMS in their latest 13F filing, including Ken Griffin, Paul Tudor Jones, Israel Englander. The largest position is worth $14.3M. See all holders.

Executive pay

Hims & Hers Health's chief executive was paid a total of $23M for the year ended Dec 31, 2025, down 7% from $24.6M the year before. In the last 12 months, Hims & Hers Health's executives and directors bought $1.2M of stock on the open market and sold $19.3M.

Chief executive, total pay$23MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$160MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$17.5MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.